CBD Advertising on Meta and Google in 2025: What Brands Can Actually Do

CBD marketers in 2025 face a familiar problem with a new twist: demand is real, but paid distribution remains tightly controlled. If you sell tinctures, topicals, capsules, or products like gummies, you cannot assume that what is legal to sell is automatically legal to advertise. Meta and Google each apply their own platform rules on top of federal, state, and local law. That means approval often depends on product type, landing-page language, geographic targeting, and whether your claims can be substantiated. The safest approach is to treat CBD advertising as a compliance exercise first and a media-buying exercise second.

1. What Changed for CBD Advertising in 2025?

The biggest shift in 2025 is not that Meta and Google suddenly opened the floodgates for CBD ads. They did not. The real change is that enforcement, documentation, and review expectations have become more structured. Advertisers now need to think more carefully about the full chain of compliance: the product itself, the wording in the ad, the wording on the landing page, the geography of the campaign, and the evidence supporting every statement.

For most brands, the practical takeaway is simple. Platform tolerance for CBD-related promotion remains narrow, and approvals can still be inconsistent. Even when a category appears conditionally permitted, that does not mean all formats, all products, or all claims are acceptable. A compliant campaign usually avoids medical language, avoids implying treatment outcomes, and uses conservative creative that focuses on product facts rather than dramatic promises.

That matters because many rejected CBD ads are not rejected for one obvious reason. Instead, they fail because several small issues stack up at once, such as unclear labeling, unsupported wellness claims, restricted ingredients, or a landing page that says more than the ad itself. In other words, compliance is judged at the campaign level, not just the headline.

1.1 Why the rules still feel confusing

CBD sits at the intersection of multiple regulatory systems. In the United States, hemp-derived products may be lawful under federal law if they meet THC limits, but the Food and Drug Administration has repeatedly stated that CBD cannot simply be marketed however a brand chooses, especially when health claims are involved. States may also impose stricter standards on sale, packaging, testing, or promotion.

Then come the platform rules. Google and Meta are private companies and can impose stricter standards than the law requires. So a product may be legal to manufacture and legal to sell in one state, yet still be ineligible for promotion through a specific ad format or account type. That gap between legality and ad eligibility is where many campaigns fail.

1.2 The core principle for advertisers

In 2025, successful CBD advertisers treat paid media as a permission-based channel. They do not begin with “How aggressive can we be?” They begin with “What can we clearly document?” That means keeping current certificates of analysis, confirming product category details, reviewing destination-page copy, and making sure every audience target aligns with local rules.

• Assume every claim will be reviewed in context
• Review ad copy and landing pages together
• Confirm state-level sales and promotion restrictions
• Keep testing and compliance records current

2. Google Ads in 2025: Narrow Permission, Strict Review

Google has historically taken a cautious approach to cannabis-related advertising, and that caution still defines the platform in 2025. Advertisers should not treat Google as broadly open to CBD. Instead, they should expect category limits, location restrictions, and strong scrutiny around whether a product or claim falls into a prohibited area.

In practical terms, Google review often extends beyond the ad text itself. The product page, shopping feed data, imagery, metadata, and sitewide language can all matter. If your site makes broad wellness or therapeutic promises, that can create problems even when the ad copy is relatively restrained. Brands promoting CBD products should therefore audit not just campaign assets, but also product descriptions, FAQs, banners, and blog content that might be reachable from the destination page.

2.1 What usually triggers trouble on Google

Google enforcement tends to become much stricter when an advertiser drifts into one of the following areas:

1. Explicit or implied medical claims
2. References suggesting diagnosis, treatment, or cure
3. Unclear THC content or product composition
4. Targeting locations where the product may not be permitted
5. Landing pages that say more than the approved ad

Even soft phrases can create risk if they imply a health outcome. Words like “relief,” “anti-inflammatory,” “anxiety support,” or “sleep treatment” may appear mild from a marketing perspective, but regulators and platforms may interpret them as health claims unless they are tightly supported and allowable under the relevant rules.

2.2 A safer Google strategy

A safer strategy on Google is to focus on product attributes rather than outcomes. For example, marketers can emphasize product format, hemp source, flavor, transparency, and testing standards instead of promising what the product will do for a person’s body or mind. Educational intent also tends to be safer than curative intent.

That does not guarantee approval, but it reduces avoidable risk. It also makes campaigns more durable because they are less dependent on gray-area phrasing that may work one week and get flagged the next.

3. Meta in 2025: High Caution Across Facebook and Instagram

Meta remains a difficult environment for CBD advertisers. In 2025, the platform still expects brands to be conservative, transparent, and extremely careful with claims. Facebook and Instagram review systems look not only at ad text and images, but also at account history, landing pages, and whether the promotion appears to involve restricted products or restricted outcomes.

One of the most important realities about Meta is that enforcement can feel uneven. Two similar ads may produce different outcomes depending on creative style, wording, review timing, or page-level signals. That inconsistency frustrates advertisers, but it also means compliance discipline matters. A campaign built on clean product information, non-medical language, and age-appropriate targeting is easier to defend and resubmit if needed.

3.1 What Meta generally dislikes

Meta has long been sensitive to ads that imply personal attributes, exploit pain points, or make people feel singled out for a health issue. CBD ads that say or imply “you are anxious,” “you have pain,” or “this fixes your sleep problem” can create problems from both a health-claim perspective and a personal-attributes perspective.

Advertisers also run into trouble when creative looks sensational, when before-and-after framing is used, or when customer testimonials overstate outcomes. A testimonial is still an advertising claim if the brand uses it in a paid promotion. If a consumer says a product “cured” something, that can still trigger enforcement when included in an ad or on a landing page.

3.2 How to improve your odds on Meta

Brands tend to perform better on Meta when they use neutral visuals, factual copy, and educational framing. The campaign should avoid medical framing, avoid references to intoxication, and avoid any implication that the product is a pharmaceutical substitute. Age-gating, geographic discipline, and careful audience exclusions can also help support a more defensible compliance posture.

• Use product-focused, not symptom-focused, creative
• Keep copy factual and specific
• Remove exaggerated testimonials from destination pages
• Document testing, sourcing, and labeling practices internally

4. Product Category Matters More Than Most Brands Expect

One of the most common mistakes in CBD marketing is treating all CBD products as one category. Platforms and regulators do not always see them that way. A topical may be evaluated differently from an ingestible. A cosmetic-style product may be treated differently from a food, beverage, supplement, or smokable item. That means your policy risk changes with the exact product format you advertise.

Marketers should map campaigns by category before they write a single ad. If a brand sells topicals, tinctures, capsules, and flower, it should not assume one policy approach covers all four. Different landing pages, claims, audience settings, and compliance reviews may be needed for each segment.

4.1 The landing page can redefine the ad

Many brands focus on the ad unit and forget that the landing page often carries the real compliance burden. If the ad is neutral but the product page makes sweeping therapeutic claims, reviewers may still disapprove the campaign. The same is true for blog content linked in the site navigation, popups that mention restricted benefits, or testimonial sections that promise disease outcomes.

In short, the destination page is part of the ad. Review it that way.

5. Labeling, Testing, and Documentation Are No Longer Optional

In 2025, strong documentation is one of the clearest differences between brands that can scale and brands that repeatedly lose ad access. Accurate labeling and current third-party testing are not just best practices. They are foundational risk controls.

At a minimum, advertisers should be able to verify product identity, batch testing, cannabinoid content, and THC limits where relevant. This matters for consumer trust, but it also matters because platform reviewers and regulators increasingly expect brands to be able to back up what appears on the label and on the landing page.

5.1 What your internal compliance file should include

1. Current certificates of analysis from reputable third-party labs
2. Product labels that match on-site descriptions
3. State availability rules and shipping restrictions
4. A claims log showing what language is approved for marketing
5. Contact information for legal or compliance review

Even if a platform never explicitly asks for every one of these materials, having them ready speeds up internal reviews and reduces the chance that a marketing team publishes risky language by accident.

5.2 Why consistency matters

Consistency across label, product page, ad copy, and support materials is critical. If your label says one thing, your certificate of analysis says another, and your website says a third, you create credibility and compliance problems at the same time. Reviewers do not need to prove bad intent to reject an ad. Apparent inconsistency alone can be enough.

6. The Biggest Risk Is Still Unsubstantiated Health Claims

If there is one rule that deserves constant repetition, it is this: do not make unsupported health claims. The FDA and the FTC have both made clear that marketers can face scrutiny when they promote products with claims about treating disease or producing unproven health outcomes. Platforms often mirror that posture in their own ad enforcement.

Many CBD brands do not intend to make medical claims, but they drift into them through shorthand language. Saying a product “supports calm” may be less risky than saying it “treats anxiety,” but context still matters. If surrounding page copy repeatedly discusses anxiety disorders, chronic pain, insomnia, or inflammation, reviewers may conclude that the overall message is therapeutic.

6.1 Claims that often create problems

• Cures, treats, prevents, or diagnoses diseases
• Guaranteed pain, stress, or sleep outcomes
• Comparisons to prescription medication
• “Doctor approved” claims without robust support
• Before-and-after promises or dramatic testimonials

The best discipline is to separate customer interest from compliant copy. Consumers may search for relief, sleep, or stress support, but brands should resist copying that exact intent language into ads unless they have a very clear legal basis and policy permission to do so.

7. State-by-State Rules Still Shape Campaign Strategy

Federal law is only part of the picture. States can set their own rules around hemp-derived products, allowable THC thresholds, packaging, age limits, and retail practices. That means campaign geography is not an afterthought. It is a core compliance decision.

If your business serves multiple states, build media plans and landing-page experiences around that reality. A one-size-fits-all national campaign can create unnecessary exposure if some states impose stricter standards or if shipping availability differs by product type.

7.1 Practical ways to reduce geographic risk

Use location targeting conservatively. Match ad reach to actual shipping coverage. Remove products from promotion in jurisdictions where the legal picture is unclear. And make sure customer support, checkout, and site messaging all reflect the same availability rules. Nothing undermines trust faster than approving traffic from a state where you cannot lawfully fulfill the order.

8. If Paid Ads Are Limited, What Should CBD Brands Do?

Smart CBD brands in 2025 do not rely on paid social or paid search alone. They build a broader demand system. That usually includes search-friendly educational content, email capture, repeat-purchase retention, creator partnerships, and strong organic branding. When platform rules tighten, diversified channels become a competitive advantage.

This is one reason influencer marketing continues to attract attention. It can help brands reach relevant audiences in a more native, content-led way. But it is not a loophole. Influencers and creators are still subject to advertising law, platform rules, disclosure expectations, and claim-substantiation standards. If a creator makes a prohibited medical claim on your behalf, that can still create brand risk.

8.1 Better alternatives to risky ad copy

When direct-response claims are constrained, brands can shift toward safer content angles:

• How products are sourced and tested
• How to read a certificate of analysis
• Differences between product formats
• Ingredient transparency and quality controls
• Shipping, storage, and usage information

These topics may feel less dramatic than aggressive performance claims, but they build trust, help conversion, and usually age better under changing platform standards.

9. A Practical Compliance Checklist for 2025

Before launching any CBD campaign on Meta or Google, run through a structured review. Doing so will not eliminate every rejection, but it will dramatically reduce preventable problems.

1. Confirm the exact product category being advertised
2. Review federal, state, and local restrictions for target markets
3. Remove unsubstantiated health and disease claims
4. Check that labels, product pages, and test results align
5. Audit all testimonials and user-generated content on the landing page
6. Use conservative audience and geography settings
7. Document your compliance review before launch
8. Monitor disapprovals and revise systematically, not emotionally

The brands that win in restricted categories are rarely the boldest. They are the most disciplined.

10. The Bottom Line for CBD Advertising in 2025

CBD advertising on Meta and Google is still possible only in limited, carefully managed circumstances. The main lesson for 2025 is not to chase loopholes. It is to build a compliance-first marketing system that respects platform rules, avoids unsupported health language, and aligns every ad with the content users see after the click.

If you remember only three things, remember these: legality does not equal ad eligibility, your landing page is part of your ad, and documentation matters. Brands that internalize those principles have a far better chance of getting approved, keeping accounts in good standing, and building durable acquisition channels in a category that remains heavily scrutinized.

Citations

• FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). (FDA)
• Health Products Compliance Guidance. (FTC)
• Google Ads Policy Help Center. (Google)
• Meta Business Help Center. (Meta)